The UK Ministry of Defence (MoD) has been forced to suspend the use of the British Army’s Ajax armoured vehicle after personnel reported symptoms of excessive noise and vibration during exercises over ...
The British Army has announced halting AJAX Training once again. Despite meeting its IOC milestone, the programme has once again been forced into a temporary pause after soldiers became unwell during ...
The Army has paused the use of its Ajax armoured vehicles after soldiers became unwell from noise and vibration during a war game exercise. Some 30 soldiers became ill across two regiments during ...
The British Army has paused the use of its Ajax armoured vehicles after approximately 30 soldiers became unwell from noise and vibration during a recent war game exercise on Salisbury Plain. Personnel ...
The multi-million pound vehicles are made in Merthyr Tydfil The Army has paused the use of its Ajax armoured vehicles after soldiers became unwell from noise and vibration during a military exercise.
The Army has paused the use of its Ajax armoured vehicles after soldiers became unwell from noise and vibration during a military exercise. About 30 soldiers became ill when training to use the ...
Army chiefs have been forced to halt the use of new Ajax armoured vehicles after troops told of vomiting and shaking so badly they struggled to control their bodies. Vibration and hearing problems ...
The British Army has paused the use of its new Ajax armoured fighting vehicles after "around 30" soldiers suffered vibration and hearing problems following a training exercise at the weekend. A ...
Some 30 soldiers became ill when training to use the armoured fighting vehicle over the weekend. The Army paused the use of the Ajax armoured vehicle after 30 soldiers reported feeling unwell during ...
Earnings call ASP Isotopes delivered a transformative Q3 2025, with radiopharmaceutical revenue up 18% YoY and three enrichment plants operational. Management reaffirmed 2026 revenue visibility and ...
ASP Isotopes Inc. (ASPI) reported its third-quarter 2025 earnings, showcasing a year-to-date revenue increase of 24% in its radiopharmaceutical segment. Despite a net loss from operations amounting to ...
Total Revenue: $4.9 million for Q3 2025, including $3.6 million from Skyline. Radiopharmaceutical Revenue: $1.3 million for Q3 2025, an 18% increase from Q3 2024. Year-to-Date Radiopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback